Creative Biolabs is globally recognized for its expertise in single domain antibody (sdAb) development. We are dedicated to crafting customized proposals to screen and identify optimal blood-brain barrier (BBB) specific sdAb candidates
with the desired functionalities to achieve our clients' goals. The comprehensive solutions provided by Creative Biolabs are designed to significantly enhance the success of your projects.
Blood-Brain Barrier (BBB) Specific SdAb
The blood-brain barrier (BBB) limits therapeutic access to the brain which poses challenges for effective drug delivery, particularly in neuroinflammatory diseases. Single-domain antibodies (sdAbs) show potential for targeting the BBB because they bypass Fc-receptor-mediated efflux, which conventional antibodies cannot avoid. Brain-drug delivery and targeting agents benefit from their small molecular weight of about 14 kDa, along with their structural stability and engineering adaptability. sdAbs enhance both brain access and cellular penetration, which allows them to bind to intracellular proteins through tissue penetration followed by internalization. The approach of linking sdAbs with shuttle peptides or proteins to use receptor-mediated transcytosis for crossing the BBB can be employed in anti-BBB sdAbs.
Creative Biolabs stands at the forefront of sdAb development by delivering comprehensive solutions that help clients develop anti-BBB sdAbs that successfully target or traverse the BBB.
Typical Features of One-Stop for Anti-BBB sdAb Development
Comprehensive strategies to formulate the most suitable solutions in dealing with BBB targets.
Highly skilled professional team with extensive expertise.
State-of-the-art platforms designed to optimize performance at every stage.
Completely adaptable design tailored to fulfill each unique requirement.
Fast turnaround time.
Consistent laboratory report with punctual updates.
Affordable price with the best quality.
Creative Biolabs has long-term devoted to the development and application of sdAbs. With our extensive experience and comprehensive sdAb development platform, Creative Biolabs is specialized in providing sdAb development services
and now offers customers elaborate anti-BBB sdAb solutions to ultimately accomplish your project requirements. For more detailed information, please feel free to contact us or directly send us an inquiry.
Case Study
In this case study, the target protein and its ligand were prepared for screening. The premade CaVHHL-S2™ library, a unique camel synthetic single domain antibody library, was used to isolate target-specific sdAb binders.
Figure 1. Process monitoring of library screening stage.
In this case study, the in-solution screening and ligand elution strategy were performed. After four rounds of biopanning, good enrichment was observed for the target, and a clear difference was found between the "Target Coating" group and the "No Coating" control.
Figure 2. Summary of monoclonal phage ELISA of the randomly picked clones and DNA sequencing.
After the biopanning, 92 clones were randomly picked for monoclonal phage ELISA and the further DNA sequencing. Finally, 4 unique clones were obtained.
Figure 1. Process monitoring of library screening stage.
Figure 2. Summary of monoclonal phage ELISA of the randomly picked clones and DNA sequencing.
